Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BBIO
stocks logo

BBIO

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
97.03M
+4375.53%
--
--
92.84M
+3298.31%
--
--
108.62M
+1746.66%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for BridgeBio Pharma, Inc. (BBIO) for FY2025, with the revenue forecasts being adjusted by 73.17% over the past three months. During the same period, the stock price has changed by 41.83%.
Revenue Estimates for FY2025
Revise Upward
up Image
+73.17%
In Past 3 Month
Stock Price
Go Up
up Image
+41.83%
In Past 3 Month
16 Analyst Rating
up Image0
Wall Street analysts forecast BBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBIO is 60.57 USD with a low forecast of 42.00 USD and a high forecast of 95.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
1 Hold
0 Sell
Strong Buy
up Image0
Current: 43.500
sliders
Low
42.00
Averages
60.57
High
95.00
up Image0
Current: 43.500
sliders
Low
42.00
Averages
60.57
High
95.00
BofA
Jason Zemansky
Buy
maintain
$50 -> $54
2025-06-25
Reason
BofA
Jason Zemansky
Price Target
$50 -> $54
2025-06-25
maintain
Buy
Reason
BofA analyst Jason Zemansky raised the firm's price target on BridgeBio to $54 from $50 and keeps a Buy rating on the shares. After speaking to key opinion leaders, the firm has greater conviction in encaleret's opportunity and more clarity into '418's potential for upside, leading it to raise forecasts, the analyst tells investors.
Wolfe Research
Outperform
initiated
$49
2025-06-18
Reason
Wolfe Research
Price Target
$49
2025-06-18
initiated
Outperform
Reason
Wolfe Research last night initiated coverage of BridgeBio with an Outperform rating and $49 price target. The company's approved transthyretin product will drive near-term stock performance, the analyst tells investors in a research note. Attruby is cheaper for patients on average, cheaper for most payers, and Part D companies have the ability to invite Medicare payers to manage, the analyst tells investors in a research note. Wolfe has high conviction for Attruby success in the near-term, but says BridgeBio's pipeline programs including achondroplasia will face meaningful competition from BioMarin and Ascendis.
Wolfe Research
Andy Chen
Outperform
initiated
2025-06-17
Reason
Wolfe Research
Andy Chen
Price Target
2025-06-17
initiated
Outperform
Reason
Wolfe Research analyst Andy Chen initiated coverage of BridgeBio with an Outperform rating.
H.C. Wainwright
Raghuram Selvaraju
Buy
maintain
$53 -> $56
2025-06-09
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$53 -> $56
2025-06-09
maintain
Buy
Reason
H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on BridgeBio to $56 from $53 and keeps a Buy rating on the shares. The firm says Attruby uptake is accelerating.
BMO Capital
Market Perform
maintain
$37 -> $42
2025-06-04
Reason
BMO Capital
Price Target
$37 -> $42
2025-06-04
maintain
Market Perform
Reason
BMO Capital raised the firm's price target on BridgeBio to $42 from $37 and keeps a Market Perform rating on the shares. The firm anticipates Attruby's U.S. sales in Q2 to be $77M-$89M, reflecting 110%-145% sequential growth and 20%-40% revenues above consensus, helping to drive 5%-15% upside in BridgeBio shares, the analyst tells investors in a research note.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Maintains
$49 → $53
2025-04-15
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$49 → $53
2025-04-15
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for BridgeBio Pharma Inc (BBIO.O) is -14.72, compared to its 5-year average forward P/E of -8.66. For a more detailed relative valuation and DCF analysis to assess BridgeBio Pharma Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.66
Current PE
-14.72
Overvalued PE
-3.99
Undervalued PE
-13.32

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-12.34
Current EV/EBITDA
-34.98
Overvalued EV/EBITDA
-5.62
Undervalued EV/EBITDA
-19.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
91.05
Current PS
20.57
Overvalued PS
163.61
Undervalued PS
18.48

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

BBIO News & Events

Events Timeline

(ET)
2025-06-30
07:36:10
BridgeBio raises $300M via parital capped monetization of European royalty
select
2025-05-20 (ET)
2025-05-20
07:41:17
BridgeBio presents data from ATTRibute-CM
select
2025-05-13 (ET)
2025-05-13
07:46:04
BridgeBio announces first participant dosed with acoramidis in ACT-EARLY
select
Sign Up For More Events
Sign Up For More Events

News

Preview
7.5
07-07NASDAQ.COM
BridgeBio Pharma (BBIO) Opinions on $300 Million Royalty Financing Deal

  • BridgeBio Pharma's Financial Moves: The company has announced a $300 million royalty financing deal for its drug acoramidis, which is seen as a strategic effort to enhance its financial position ahead of significant product launches and late-stage programs, generating interest in its growth potential within the biotech sector.

  • Insider Trading and Analyst Ratings: Recent insider trading shows 37 sales with no purchases of $BBIO stock over the past six months, while institutional investors have shown mixed activity. Analysts remain optimistic, with two firms issuing buy ratings and none issuing sell ratings on the stock.

Preview
6.5
07-03NASDAQ.COM
Is Pfizer Stock a Yield Trap?

  • Pfizer's Financial Outlook: Pfizer faces significant revenue losses due to upcoming patent expirations, particularly for its key drug Eliquis, which could reduce annual revenue by $17-$18 billion from 2026 to 2028. Despite this, the company has a strong dividend history and a productive pipeline of new drugs that may help maintain its dividend payouts.

  • Investment Considerations: While Pfizer's stock offers an attractive yield compared to the S&P 500 average, potential investors should be cautious as drug launches are unpredictable, and there is a risk of dividend reductions if targets are not met. The Motley Fool recommends exploring other stocks that may offer better returns.

Preview
4.5
07-01CNBC
These Nasdaq stocks have led the bounce since 'liberation day' back to all-time highs

  • Market Recovery Highlights: The S&P 500 reached an all-time high, driven by a strong recovery in tech stocks, particularly following President Trump's tariff announcements.

  • Top Performing Stocks: Notable stocks like BridgeBio Pharma and AppLovin have shown significant gains, with analysts predicting further upside potential based on their performance and buy ratings.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is BridgeBio Pharma Inc (BBIO) stock price today?

The current price of BBIO is 43.5 USD — it has decreased -1.11 % in the last trading day.

arrow icon

What is BridgeBio Pharma Inc (BBIO)'s business?

BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

arrow icon

What is the price predicton of BBIO Stock?

Wall Street analysts forecast BBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBIO is 60.57 USD with a low forecast of 42.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is BridgeBio Pharma Inc (BBIO)'s revenue for the last quarter?

BridgeBio Pharma Inc revenue for the last quarter amounts to 116.63M USD, decreased -44.76 % YoY.

arrow icon

What is BridgeBio Pharma Inc (BBIO)'s earnings per share (EPS) for the last quarter?

BridgeBio Pharma Inc. EPS for the last quarter amounts to -0.88 USD, increased 340.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for BridgeBio Pharma Inc (BBIO)'s fundamentals?

The market is revising Upward the revenue expectations for BridgeBio Pharma, Inc. (BBIO) for FY2025, with the revenue forecasts being adjusted by 73.17% over the past three months. During the same period, the stock price has changed by 41.83%.
arrow icon

How many employees does BridgeBio Pharma Inc (BBIO). have?

BridgeBio Pharma Inc (BBIO) has 725 emplpoyees as of July 08 2025.

arrow icon

What is BridgeBio Pharma Inc (BBIO) market cap?

Today BBIO has the market capitalization of 8.26B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free